CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients
| Autor: | S Bilgen, M Gulhan, Mumtaz Iscan, S C Kunak, Sinan Süzen, Ahmet Oguz Ada, F Hancer, B Kurt, S Alpar |
|---|---|
| Přispěvatelé: | Giresun Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri, Farmakoloji Ana Bilim Dalı, Kunak, Celalettin Semih, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kurt, Emine Bahar, İşcan, Mümtaz |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Survival CYP1B1 urologic and male genital diseases survival polymorphism chemistry.chemical_compound Exon GSTP1 Cytochrome P-450 Enzyme System Carcinoma Non-Small-Cell Lung Internal medicine Cytochrome P-450 Genotype Cytochrome P-450 CYP1A1 medicine Carcinoma Humans Polymorphism Lung cancer neoplasms Non Small Cell Lung Cancer Aged Glutathione Transferase glutathione S-transferase Polymorphism Genetic non small cell lung cancer business.industry Hazard ratio Glutathione Middle Aged medicine.disease Molecular biology Glutathione S-Transferase pi chemistry Cytochrome P-450 CYP1B1 Female Aryl Hydrocarbon Hydroxylases business Glutathione S-Transferase |
| Zdroj: | Neoplasma. 57:512-521 |
| ISSN: | 0028-2685 |
| Popis: | Kurt, Emine Bahar/0000-0002-3495-2339; Ada, Ahmet Oguz/0000-0001-9987-0572; Suzen, Sinan/0000-0003-1779-5850 WOS: 000286494400004 PubMed: 20845989 Several polymorphisms in cytochrome P-450s (CYP)s and Glutathione S-transferases (GST)s have been reported to be associated with survival rates of patients with non-small cell lung cancer (NSCLC) but the studies in this regard are scarce and the results are contradictory. In this study, CYP1A1 (Ile462Val), CYP1B1(Asn453Ser), GST M1, GSTP1 exon 5 (Ile105Val) and exon 6(Ala114Val) and GSTT1 polymorphisms were determined in 138 patients with advanced NSCLC to evaluate their role in survival. Of the studied GYP and GST polymorphisms only GSTP1 exon 6 variant significantly altered (improved) the survival compared to wild type (p=0.036) with median survival of 22.2 months and 16.1 months, respectively. Multivariate analysis also revealed a significant reduction of adjusted hazard ratio of death associated only with the GSTP1 exon 6 variant genotype of 0.45(95% confidence interval (95% CI), 0.23-0.89,p=0.022). These results show that the GSTP1 exon 6 variant genotype is associated with improved survival in the patients with advanced NSCLC. Research Fund of Ankara UniversityAnkara University [2006-08-03-002 HPD, 2007-08-03-005 HPD] This research was supported by the grants from Research Fund of Ankara University Nos: 2006-08-03-002 HPD and 2007-08-03-005 HPD |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|